Patents by Inventor Gordon Ringold

Gordon Ringold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250339388
    Abstract: Phenylalanine-based inhibitors of the Large Amino Acid Transporter 1 (LAT1) are disclosed. The compounds are useful in modulating the transcellular transport of substrates of LAT1 such as large neutral amino acids. The compounds are useful in immunomodulation therapies.
    Type: Application
    Filed: July 9, 2025
    Publication date: November 6, 2025
    Inventors: Bernd JANDELEIT, Guangyao Gao, Wolf-Nicolas Fischer, Gordon Ringold
  • Publication number: 20250319046
    Abstract: Phenylalanine-based inhibitors of the Large Amino Acid Transporter 1 (LAT1) are disclosed. The compounds are useful in modulating the transcellular transport of substrates of LAT1 such as large neutral amino acids. The compounds are useful in immunomodulation therapies.
    Type: Application
    Filed: February 25, 2025
    Publication date: October 16, 2025
    Inventors: BERND JANDELEIT, GUANGYAO GAO, WOLF-NICOLAS FISCHER, GORDON RINGOLD
  • Patent number: 12427124
    Abstract: Phenylalanine-based inhibitors of the Large Amino Acid Transporter 1 (LAT1) are disclosed. The compounds are useful in modulating the transcellular transport of substrates of LAT1 such as large neutral amino acids. The compounds are useful in immunomodulation therapies.
    Type: Grant
    Filed: February 25, 2025
    Date of Patent: September 30, 2025
    Assignee: Maxymune Therapeutics, Inc.
    Inventors: Bernd Jandeleit, Guangyao Gao, Wolf-Nicolas Fischer, Gordon Ringold
  • Publication number: 20190185413
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 20, 2019
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Patent number: 10246406
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 2, 2019
    Assignee: QUADRIGA BIOSCIENCES, INC.
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Publication number: 20180297935
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Application
    Filed: May 22, 2018
    Publication date: October 18, 2018
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Patent number: 10017459
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 10, 2018
    Assignee: Quadriga Biosciences, Inc.
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Publication number: 20170362166
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Application
    Filed: September 1, 2017
    Publication date: December 21, 2017
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Patent number: 9783487
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 10, 2017
    Assignee: Quadriga Biosciences, Inc.
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Publication number: 20170036992
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Application
    Filed: August 3, 2016
    Publication date: February 9, 2017
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Publication number: 20160346240
    Abstract: Compositions and methods for protecting normal, healthy cells during chemotherapy are disclosed. The methods include administering one or more compounds that inhibit the cell cycle of rapidly regenerating normal cells and a chemotherapeutic agent. The cell cycle inhibitors can be administered prior to administration of a chemotherapeutic agent. The chemotherapeutic agents can be ?-substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs. Pharmaceutical compositions comprising the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and uses thereof are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs can be administered in conjunction with one or more compounds that inhibit the cell cycle of rapidly proliferating normal healthy cells. The cell cycle inhibitors can ameliorate the adverse effects of the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs.
    Type: Application
    Filed: August 10, 2016
    Publication date: December 1, 2016
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Publication number: 20050059101
    Abstract: Bivalent molecules that target cancer cells by simultaneously binding to at least two different compounds, and methods for their use in treating, diagnosing, imaging and staging cancers are provided.
    Type: Application
    Filed: September 10, 2004
    Publication date: March 17, 2005
    Inventor: Gordon Ringold